益生菌对胰腺癌的结果是有益的还是有害的?
1Division of Gastroenterology, Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, 101, Daehak-Ro, Jongno-Gu, Seoul, Republic of Korea. rhytksa@snu.ac.kr.
Probiotics and antimicrobial proteins
|December 23, 2024
概括
口服益生菌可以改善胰腺癌患者接受息化疗的整体生存率. 这项研究表明了潜在的益处,尽管需要进一步研究免疫机制.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 微生物组研究 微生物组研究
背景情况:
- 胰腺癌的结果受到瘤微环境 (TME) 的影响,包括 CD8+ T 细胞等免疫细胞.
- 胰腺组织含有可影响瘤生长和免疫反应的微生物组.
- 特定的细菌 (Bacteroides,Lactobacillus,Peptoniphilus) 与较差的胰腺癌预后有关.
研究的目的:
- 研究口服益生菌对胰腺癌患者结局的影响.
- 为了比较接受益生菌和对照组的患者之间的无进展生存 (PFS) 和整体生存 (OS).
主要方法:
- 来自首尔国立大学医院的胰腺癌患者 (年龄≥18) 的回顾性评估 (2011年1月 - 2023年1月).
- 分析包括在没有放射治疗或切除的情况下接受息化疗的患者.
- 对照组和口服益生菌组之间的生存指标的比较.
主要成果:
- 在对照组和益生菌组之间观察到总生存时间 (OS) 的显著差异 (中位数OS:10个月与12个月,p=0.026).
- 口服益生菌在这个队列中显示出对胰腺癌结果的潜在积极影响.
结论:
- 口服益生菌可能为接受缓性化疗的胰腺癌患者提供生存益处.
- 需要进行进一步的研究,以阐明益生菌观察到的影响背后的免疫机制.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
70
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
70
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328